Iambic Therapeutics

Headquarters and Global Presence

Iambic is based in San Diego, California, and runs discovery and development across U.S. and international networks. Clinical studies are conducted through multi-center trial sites, with expansion outside the U.S. as programs progress.

Founding and History

Iambic was founded to apply physics-informed AI to protein–ligand modeling and small-molecule design, with the goal of shortening optimization timelines and improving developability. The company has raised multiple venture financings and has advanced at least one internally discovered asset into human clinical testing.

Therapy Areas and Focus

Iambic’s disclosed pipeline is weighted toward oncology, with programs targeting:

• HER2-driven cancers, including oncogenic mutations
• Cell-cycle dysregulation pathways
• Additional oncology targets (including kinesin biology)
  The company also lists a neurological indication program in discovery, indicating platform application beyond oncology.

Technology Platforms and Modalities

Iambic focuses on oral small molecules and positions its platform around:

• Structure- and physics-informed AI for protein–ligand interaction modeling (including NeuralPLexer)
• Iterative, high-throughput DMTA cycles to optimize potency, selectivity, PK, safety margins, and developability
• Coverage of multiple target classes and mechanisms (orthosteric inhibitors, allosteric inhibitors, protein–protein interaction modulation)

Programs and Clinical Pipeline

Lead disclosed programs include:

• IAM1363 (HER2 wild type and mutant inhibitor): Phase I clinical trial (patient dosing began March 2024). Designed as a selective HER2 inhibitor intended to spare EGFR.
• IAM-C1 (dual CDK2/4 inhibitor): discovery/IND-enabling stage; positioned as a selective approach to CDK2/4 while avoiding other CDKs.
• KIF18A allosteric inhibitor: discovery/lead optimization stage for oncology.
• GPCR target (undisclosed): discovery stage; neurological indication.

Strategic Partnerships

Iambic collaborates with partners to apply its platform to external targets and co-develop selected assets. A recent example is a technology and discovery collaboration with Takeda focused on AI-enabled small-molecule discovery.

Key Personnel

• Tom Miller, PhD, Co-Founder and Chief Executive Officer
• Fred Manby, PhD, Co-Founder and Chief Technology Officer
• Neil Josephson, MD, Chief Medical Officer
• Pete Olson, PhD, Chief Scientific Officer
• Michael Secora, PhD, Chief Financial Officer and Chief Corporate Development Officer

FAQ Section